AMLX
Amylyx Pharmaceuticals Inc
28.10$
-3.5%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | – | 100.0% | – | – | – | – | – | – | – | – | |
| 5.1% | 8.6% | 131.3% | – | 194.5% | – | – | – | – | – | – | – | – | |
| 94.9% | 91.4% | -31.3% | – | -94.5% | – | – | – | – | – | – | – | – | |
| 29.2% | 41.4% | 41.3% | – | 5,105.0% | – | – | – | – | – | – | – | – | |
| 47.4% | 39.4% | 65.2% | – | 4,285.6% | – | – | – | – | – | – | – | – | |
| 76.7% | 89.6% | 106.5% | – | 18,093.3% | – | – | – | – | – | – | – | – | |
| 18.2% | 1.8% | -137.8% | – | -18,187.7% | – | – | – | – | – | – | – | – | |
| – | 3.2% | – | – | – | – | – | – | – | – | – | – | – | |
| 21.8% | 6.0% | -133.7% | – | -17,476.9% | – | – | – | – | – | – | – | – | |
| 1.5% | 1.6% | 0.3% | – | -17,476.9% | – | – | – | – | – | – | – | – | |
| 20.3% | 4.4% | -134.0% | – | -17,476.9% | – | – | – | – | – | – | – | – | |
| 22.1% | 6.2% | -133.4% | – | -17,423.8% | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.